
Jennifer Giltnane

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6383476/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell, 2022, 40, 289-300.e4.	16.8	148
2	Automated Dissection Protocol for Tumor Enrichment in Low Tumor Content Tissues. Journal of Visualized Experiments, 2021, , .	0.3	2
3	Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer. Cancer Cell, 2021, 39, 928-944.e6.	16.8	158
4	Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. Cell, 2019, 178, 949-963.e18.	28.9	131
5	CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms. Cancer Research, 2019, 79, 3916-3927.	0.9	26
6	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. Clinical Cancer Research, 2018, 24, 2517-2529.	7.0	26
7	Multiplexed ion beam imaging analysis for quantitation of protein expresssion in cancer tissue sections. Laboratory Investigation, 2017, 97, 992-1003.	3.7	33
8	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metabolism, 2017, 26, 633-647.e7.	16.2	449
9	Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. Clinical Cancer Research, 2017, 23, 6138-6150.	7.0	94
10	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Science Translational Medicine, 2017, 9, .	12.4	91
11	Evaluating feasibility of an automated 3-dimensional scanner using Raman spectroscopy for intraoperative breast margin assessment. Scientific Reports, 2017, 7, 13548.	3.3	45
12	The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. ELife, 2016, 5, .	6.0	100
13	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. Science Translational Medicine, 2016, 8, 334ra53.	12.4	105
14	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clinical Cancer Research, 2016, 22, 1499-1509.	7.0	428
15	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. Cancer Research, 2015, 75, 405-414.	0.9	53
16	Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 1757-1767.	7.0	529
17	PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin. Haematologica, 2014, 99, e148-e151.	3.5	29